CEL-Seq2: sensitive highly-multiplexed single-cell RNA-Seq. What is damaging the kidney in lupus nephritis? Nat. Increased tubulointerstitial recruitment of human CD141(hi) CLEC9A(+) and CD1c(+) myeloid dendritic cell subsets in renal fibrosis and chronic kidney disease. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and Bayesian meta-analysis.
Medical immunology pdf update#
Update on clinical trials in systemic lupus erythematosus. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Gene expression of immune cells in urine and kidney was highly correlated, which would suggest that urine might serve as a surrogate for kidney biopsies.Ĭostenbader, K.
Two chemokine receptors, CXCR4 and CX3CR1, were broadly expressed, implying a potentially central role in cell trafficking. A clear interferon response was observed in most cells. We found evidence of local activation of B cells correlated with an age-associated B-cell signature and evidence of progressive stages of monocyte differentiation within the kidney. Our analysis revealed 21 subsets of leukocytes active in disease, including multiple populations of myeloid cells, T cells, natural killer cells and B cells that demonstrated both pro-inflammatory responses and inflammation-resolving responses. To develop mechanistic hypotheses of disease, we analyzed kidney samples from patients with lupus nephritis and from healthy control subjects using single-cell RNA sequencing. Lupus nephritis is a potentially fatal autoimmune disease for which the current treatment is ineffective and often toxic. Nature Immunology volume 20, pages 902–914 ( 2019) Cite this article the Accelerating Medicines Partnership in SLE network.The immune cell landscape in kidneys of patients with lupus nephritis
0 kommentar(er)
